RNA Nanotherapeutics was founded on deep scientific expertise in both basic sciences in understanding molecular mechanisms underlying cancer and treatment resistance, and translational research in the state-of-the-art RNA nanotechnology.
Our research was initiated through generous support by cancer survivors and made possible through continued funding by many grassroots cancer foundations and federal agencies. Our team has graduated from the University of Cincinnati 1819 Innovation Hub venture lab and is currently supported by Ohio Third Frontier Technology Validation and Start-up Fund (TVSF) and Entrepreneurial Services Provider (ESP) Program seed award to commercialize this technology. We are committed to standing alongside and building strong partnerships with patients, their families, and our cancer community to develop better, safer and more effective next-generation therapeutics to improve patient treatment outcome and quality of life.
We are continually seeking opportunities and partnerships with individuals, investors, and biopharmaceutical companies to identify areas of common interest and address unmet medical needs in cancer therapy and the treatment of other diseases.